FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 169 filers reported holding FATE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 9.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,508,000 | -68.7% | 67,300 | -65.4% | 0.20% | -72.7% |
| Q2 2022 | $4,817,000 | -39.7% | 194,400 | -5.6% | 0.75% | -27.1% |
| Q1 2022 | $7,983,000 | +1650.7% | 205,900 | +2539.7% | 1.03% | +2139.1% |
| Q4 2021 | $456,000 | -26.6% | 7,800 | +14.2% | 0.05% | -43.9% |
| Q4 2020 | $621,000 | +60.1% | 6,830 | -29.7% | 0.08% | -60.2% |
| Q3 2020 | $388,000 | -65.7% | 9,712 | -70.6% | 0.21% | -68.1% |
| Q2 2020 | $1,132,000 | +407.6% | 33,000 | +189.5% | 0.64% | +200.0% |
| Q4 2019 | $223,000 | – | 11,400 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $34,095 | 9.92% |
| Redmile Group, LLC | 12,957,222 | $130,738,370 | 5.35% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $10,465,913 | 2.67% |
| Casdin Capital, LLC | 2,050,000 | $20,684,500 | 1.60% |
| DAFNA Capital Management LLC | 550,940 | $5,558,985 | 1.57% |
| Artal Group S.A. | 2,600,000 | $26,234 | 1.46% |
| Monaco Asset Management SAM | 250,000 | $2,522,500 | 0.76% |
| Parametrica Management Ltd | 32,254 | $325,443 | 0.67% |
| Boxer Capital, LLC | 1,250,000 | $12,612,500 | 0.66% |
| Bellevue Group AG | 4,861,279 | $49,050,305 | 0.65% |